These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37350801)

  • 1. PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients.
    Asghar K; Bashir S; Ali Rana I; Abu Bakar M; Farooq A; Hassan M; Asif Z; Afzal M; Masood I; Ishaq M; Tahseen M; Bilal S; Mehmood S; Kanwal N; Ud Din I; Loya A
    J Hepatocell Carcinoma; 2023; 10():921-934. PubMed ID: 37350801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Indoleamine 2,3-Dioxygenase Expression along with Low Bridging Integrator-1 Expression in Hepatocellular Carcinoma Patients.
    Asghar K; Rana IA; Abubakar M; Hasham K; Tahseen M; Bilal S; Mehmood S; Farooq A; Siddique K; Loya A
    Asian Pac J Cancer Prev; 2023 May; 24(5):1591-1600. PubMed ID: 37247278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
    Mandarano M; Bellezza G; Belladonna ML; Van den Eynde BJ; Chiari R; Vannucci J; Mondanelli G; Ludovini V; Ferri I; Bianconi F; Del Sordo R; Cagini L; Albini E; Metro G; Puma F; Sidoni A
    Virchows Arch; 2019 Feb; 474(2):159-168. PubMed ID: 30448912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indoleamine 2,3-dioxygenase expression and overall survival in patients diagnosed with breast cancer in Pakistan.
    Asghar K; Loya A; Rana IA; Tahseen M; Ishaq M; Farooq A; Bakar MA; Masood I
    Cancer Manag Res; 2019; 11():475-481. PubMed ID: 30655699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
    Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
    Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma.
    Chinnadurai R; Scandolara R; Alese OB; Arafat D; Ravindranathan D; Farris AB; El-Rayes BF; Gibson G
    Front Oncol; 2020; 10():1632. PubMed ID: 33014820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors.
    Samiei A; Gjertson DW; Memarzadeh S; Konecny GE; Moatamed NA
    Diagn Pathol; 2022 Sep; 17(1):70. PubMed ID: 36104728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of immune checkpoints (PD-L1 and IDO) and tumour-infiltrating lymphocytes in breast cancer.
    Alkhayyal N; Elemam NM; Hussein A; Magdub S; Jundi M; Maghazachi AA; Talaat IM; Bendardaf R
    Heliyon; 2022 Sep; 8(9):e10482. PubMed ID: 36097493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
    Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
    Volaric A; Gentzler R; Hall R; Mehaffey JH; Stelow EB; Bullock TN; Martin LW; Mills AM
    Am J Surg Pathol; 2018 Sep; 42(9):1216-1223. PubMed ID: 29901571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
    Hacking S; Chavarria H; Jin C; Perry A; Nasim M
    Pathol Res Pract; 2020 Apr; 216(4):152847. PubMed ID: 32085927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.
    Seeber A; Klinglmair G; Fritz J; Steinkohl F; Zimmer KC; Aigner F; Horninger W; Gastl G; Zelger B; Brunner A; Pichler R
    Cancer Sci; 2018 May; 109(5):1583-1591. PubMed ID: 29498788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.
    Wei YF; Chu CY; Chang CC; Lin SH; Su WC; Tseng YL; Lin CC; Yen YT
    Lung Cancer; 2018 Nov; 125():35-42. PubMed ID: 30429036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder.
    Kim D; Kim JM; Kim JS; Kim S; Kim KH
    J Clin Med; 2020 Apr; 9(5):. PubMed ID: 32349330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
    Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.
    Hacking S; Vitkovski T; Jain S; Jin C; Chavarria H; Wu D; Nasim M
    Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):201-208. PubMed ID: 32842025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant.
    Teng CF; Li TC; Wang T; Wu TH; Wang J; Wu HC; Shyu WC; Su IJ; Jeng LB
    J Hepatocell Carcinoma; 2020; 7():385-401. PubMed ID: 33365286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.